Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

PURPOSE: Anaplastic lymphoma kinase (ALK) rearrangements are important therapeutic targets in non-small cell lung cancer (NSCLC) that confer sensitivity to the ALK inhibitors crizotinib and ceritinib. To determine the outcome of sequential treatment with crizotinb and ceritinib, we retrospectively e...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Gainor, Justin F., Tan, Daniel S.W., De Pas, Tomasso, Solomon, Benjamin J., Ahmad, Aziah, Lazzari, Chiara, de Marinis, Filippo, Spitaleri, Gianluca, Schultz, Katherine, Friboulet, Luc, Yeap, Beow Y., Engleman, Jeffrey A., Shaw, Alice T.
Format: Artigo
Sprog:Inglês
Udgivet: 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4470734/
https://ncbi.nlm.nih.gov/pubmed/25724526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3009
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker